Pharma channel feed

As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ap­proval

6 years ago
R&D

More than half of its gross sales ul­ti­mate­ly went to pay­ers as re­bates, Sanofi says

6 years ago

FDA re­quires boxed warn­ing for Sin­gu­lair and its gener­ics

6 years ago
FDA+

Vil­i­fied for high drug prices, what does the prof­itabil­i­ty of ma­jor US phar­ma com­pa­nies look like?

6 years ago

AM­AG CMO hits the ex­it just as biotech search­es for new CEO to right a ship rocked by Mak­e­na con­tro­ver­sy

6 years ago
People

Add Take­da and Al­ny­lam to the menu of glob­al drug­mak­ers look­ing to stymie the coro­n­avirus epi­dem­ic

6 years ago
R&D
Coronavirus

As costs con­tin­ue to soar ever high­er, As­traZeneca sees new HQ stick­er price gy­rate to $1.28B

6 years ago

Karyopharm spot­lights PhI­II re­sults af­ter con­tro­ver­sial FDA ap­proval

6 years ago
R&D

The FDA OKs gener­ic Dara­prim, the Mar­tin Shkre­li ther­a­py that trig­gered an un­end­ing tem­pest over drug pric­ing

6 years ago

Why FDA can’t dis­close the first coro­n­avirus-re­lat­ed drug short­age

6 years ago
FDA+
Coronavirus

Bio­haven scores CGRP OK for acute mi­graine — can the com­mer­cial team catch up with Al­ler­gan on its de­but?

6 years ago

Mallinck­rodt, once the na­tion’s largest oxy­codone pro­duc­er, an­nounces ten­ta­tive $1.6B set­tle­ment

6 years ago
Deals

No­var­tis' plans to wres­tle Eylea mar­ket share take a hit as Beovu is linked to safe­ty con­cerns

6 years ago
FDA+

Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

6 years ago
China

The fourth CGRP mi­graine drug is here. Time for Lund­beck to prove it's worth $2B

6 years ago
FDA+

Es­pe­ri­on's goldilocks cho­les­terol fight­er wins FDA ap­proval — will its 'tra­di­tion­al' pric­ing ap­proach spur adop­tion?

6 years ago
FDA+

Phar­ma­co­ge­net­ics: FDA re­leas­es ta­ble of gene-drug in­ter­ac­tions

6 years ago
FDA+

Don't let Ab­b­Vie fool FTC with an easy di­vesti­ture, plead crit­ics in lat­est at­tack on $63B Al­ler­gan buy­out

6 years ago
Deals

Auste­do, Teva's bright spot as it ex­e­cutes turn­around, fails two Touret­te's tri­als

6 years ago

As blue­bird makes com­mer­cial progress in Eu­rope, US ap­pli­ca­tion for Zyn­te­glo suf­fers de­lay

6 years ago
FDA+

For­mer No­var­tis ex­ec pleads guilty to gener­ic price fix­ing

6 years ago

New en­tries, price hikes spur changes among the 20 most ex­pen­sive drugs — though not the kind politi­cians like to see

6 years ago

Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

6 years ago
R&D
Coronavirus

The list of the 11 block­busters-to-be in line for a 2020 launch high­light agony and ec­sta­sy of drug R&D

6 years ago
First page Previous page 259260261262263264265 Next page Last page
A service from the Financial Times